摘要
目的 观察吉非替尼一线治疗老年晚期肺腺癌患者的临床疗效及不良反应.方法 81例初治晚期肺腺癌不吸烟、不适于全身化疗的老年患者,接受吉非替尼治疗至疾病进展或不良反应不可耐受,观察近期疗效、体力状态改善情况及不良反应.结果 81例患者均可进行疗效评估,部分缓解21例（25.9％）,疾病稳定39例（48.1％）,45例（55.5％）的患者治疗后体力状态有所改善.主要不良反应为Ⅰ度皮疹、乏力、腹泻.结论 吉非替尼一线治疗老年人晚期肺腺癌疗效确切,耐受性良好.
Objective To evaluate the efficacy and adverse effects of gefitinib as the first line treatment in elderly patients with lung adenocarcinoma.Methods 81 elderly patients of previously untreated advanced lung adenocarcinoma,who were non-smokers and unsuitable for chemotherapy,received gefitinib treatment until disease progression or intolerable toxicities occurred.The curative effect performance status of improvement and adverse effects were observed.Results All of the patients were evaluable.Partial response rate and stable disease rate of gefifinib were 25.9 % （21/81） and 48.1% （39/81）,respectively.55.5 % （45/81）of patients had performance status improved after treatment.Conclusion Gefitinib has curative effect and is well tolerated in the treatment of elderly patients with previously untreated advanced lung adenocarcinoma.
出处
《肿瘤研究与临床》
CAS
2013年第5期306-308,共3页
Cancer Research and Clinic
关键词
肺肿瘤
吉非替尼
一线治疗
老年
Lung neoplasms
Gefitinib
First-line treatment
Elderly
